点支架移植术治疗Stanford B型主动脉夹层及壁内血肿的初步结果
该研究基于单中心前瞻性数据库,回顾1997至2018年急性/亚急性Stanford B型主动脉夹层或壁内血肿行TEVAR的183例患者,其中22例接受点支架移植术(SSG)。技术成功率100%,随访中95.5%患者假腔血栓形成,68.2%实现主动脉重塑,无逆行夹层或支架诱发新入口,住院及30天死亡率0%。
要点
- SSG技术成功率100%,假腔血栓形成率95.5%,主动脉重塑率68.2%。
- 无逆行夹层、支架诱发新入口、卒中或脊髓损伤发生。
- 住院及30天死亡率0%,随访总死亡率22.7%,再干预4/22例。
核心结论
- 在经选择的急性/亚急性Stanford B型主动脉夹层或壁内血肿患者中,SSG显示出良好的技术和形态学结果。
- 患者分配至SSG仍需个体化决策,尚需前瞻性大规模长期数据进一步优化应用。
研究设计与样本
- 回顾性分析单中心前瞻性维护数据库,1997至2018年因急性/亚急性Stanford B型主动脉夹层或壁内血肿行TEVAR的183例患者中,22例接受SSG(7例女性,中位年龄62岁,范围35-79岁)。
- 主要研究终点为技术成功,主要形态学终点为假腔血栓形成/主动脉重塑,次要终点为TEVAR相关死亡/并发症及再干预,中位随访28.5个月(5天至15.6年)。
主要发现
- 主要技术成功率为100%(22/22)。
- 随访期间21例(95.5%)观察到假腔血栓形成,中位时间6天(0天至2.7年),其中局限/广泛假腔血栓形成分别为9例和12例。
- 22例中15例(68.2%)实现主动脉重塑,中位时间360天(3天至7.2年),局限/广泛重塑分别为8/15和7/15。
- 未观察到逆行夹层或支架诱发新入口,无卒中或脊髓损伤发生,再干预4/22例。
- 住院死亡率和30天死亡率均为0%,随访期间总死亡率22.7%(5/22)。
临床怎么用
- 对于近端锚定区病变的急性/亚急性Stanford B型主动脉夹层或壁内血肿患者,SSG可作为一种个体化选择的局部腔内治疗方式。
- SSG使用单个短器械覆盖病变锚定区,针对位于下游(主动脉4区和5区)的主要入口/壁内血液聚集。
局限性
- 样本量小(22例),患者选择个体化,非随机设计,随访时间异质性大(中位28.5个月,范围5天至15.6年)。
- 患者分配至SSG仍为个体化决定,需前瞻性大规模长期数据进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Optimal treatment for patients with diseased proximal landing zones in acute/subacute Stanford type B dissection and intramural haematoma remains unclear. This study describes the preliminary outcomes of a localized endovascular treatment [spot-stent grafting (SSG)] of main entries/intramural blood pooling located downstream (aortic zones 4 and 5) using one single short device comprising diseased landing zones, looking particularly at the technical and morphological outcomes. METHODS: Patients undergoing thoracic endovascular aortic repair (TEVAR) for acute/subacute aortic dissection Stanford type B/intramural haematoma Stanford type B between 1997 and 2018 were identified from a prospectively maintained institutional database. In a total of 183 cases, 22 patients (7 women; median age 62 years; range 35-79 years) received SSG. The primary study end point was technical success. The primary morphological end point was false lumen thrombosis/aortic remodelling. Secondary end points were TEVAR-related mortality/morbidity and reinterventions. The median follow-up was 28.5 months (5 days-15.6 years). RESULTS: The primary technical success rate was 100% (22/22). During follow-up, false lumen thrombosis was seen in 21 patients (95.5%) at a median of 6 days (0 days to 2.7 years) after the index procedure (limited/extended false lumen thrombosis: n = 9 vs 12). Aortic remodelling was achieved in 15 of 22 patients (68.2%) at a median of 360 days (3 days to 7.2 years). Limited/extended remodelling was observed in 8/15 and 7/15, respectively. Retrograde dissection or stent graft-induced new entry was not observed. No stroke or spinal cord injury occurred. Reinterventions were performed in 4/22 cases. The in-hospital mortality and 30-day mortality were 0%. Overall mortality during the follow-up period was 22.7% (5/22). CONCLUSIONS: This study shows favourable technical and morphological results for SSG in selected patients with acute/subacute aortic dissection Stanford type B/intramural haematoma Stanford type B. Patient allocation to SSG remains individual. Prospective large-scale long-term data may allow refinement of the application.
引用
- Meisenbacher K, Böckler D, Geisbüsch P, et al. Preliminary results of spot-stent grafting in Stanford type B aortic dissection and intramural haematoma. Eur J Cardiothorac Surg. 2020. PMID: 32712654. doi:10.1093/ejcts/ezaa198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。